Skip to Main Content

Schizophrenia Inpatient – Otsuka-00035


About the Study

Treatment for worsening of symptoms in patients with schizophrenia.

The primary objective of this study is to evaluate the efficacy, safety, and tolerability of SEP-363856 (75 mg to 100 mg /daily) compared to a placebo in adults experiencing an acute exacerbation of schizophrenia.

This study is sponsored by Otsuka Pharmaceutical.


Eligibility

You may be eligible to participate in this study if you:

  • are between the ages of 18 – 65 years old

  • have been diagnosed with schizophrenia, and currently experiencing active symptoms

  • are willing to spend 6 to 8 weeks in our 24-hour overnight observation unit


If chosen for this study, you will be compensated for every study visit that you complete and we can provide transportation if needed.

If you are interested in participating in this clinical trial, please call our friendly staff at 773-989-8313 ext. 116 today. You can also fill out the contact form below.